^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JCAR014

i
Other names: JCAR014, anti-CD19-4-1BB-zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes, CD19 fully human scFv CAR T cell therapy, JCAR 014, JCAR-014
Company:
BMS, Fred Hutchinson Cancer Center
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs: